MOCS3-2 Antibody

What is MOCS3 and why is it important in research?

MOCS3 plays a central role in two critical cellular processes: 2-thiolation of mcm(5)S(2)U at tRNA wobble positions (specifically in cytosolic tRNA(Lys), tRNA(Glu), and tRNA(Gln)), and biosynthesis of the molybdenum cofactor. MOCS3 accomplishes this by mediating the C-terminal thiocarboxylation of sulfur carriers URM1 and MOCS2A. The N-terminus of MOCS3 first activates URM1 and MOCS2A as acyl-adenylates (-COAMP), then the persulfide sulfur on the catalytic cysteine is transferred to form thiocarboxylation (-COSH) of their C-terminus . This reaction involves hydrogen sulfide generated from the persulfide intermediate acting as a nucleophile. Importantly, MOCS3 does not use thiosulfate as a sulfur donor but relies on NFS1 as the sulfur donor for thiocarboxylation reactions . Given its critical role in these fundamental cellular processes, MOCS3 antibodies are valuable tools for investigating normal cellular function and potentially disease states.

What applications are MOCS3 antibodies validated for?

Commercial MOCS3 antibodies have been validated for multiple research applications. Based on the available data, they are primarily suitable for Western Blotting (WB), with some antibodies additionally validated for Immunohistochemistry on paraffin-embedded sections (IHC-P) and Immunofluorescence (IF) . The polyclonal rabbit antibody ab154107 has been cited in published research and is validated for WB with human samples . Another antibody, ab229827, is validated for both WB and IHC-P in human samples . The antibody ABIN7307034 has broader application validation, including WB, IHC, IF, and Immunochromatography (IC) . When designing experiments, researchers should select antibodies that have been specifically validated for their intended application to ensure reliable results.

How should Western blotting protocols be optimized for MOCS3 detection?

For optimal Western blotting detection of MOCS3, consider the following methodological approach:

• Sample preparation: Use RIPA buffer supplemented with protease inhibitors for efficient protein extraction.

• Sample loading: Load 20-40 μg of total protein per lane for cell lysates or tissue homogenates.

• Gel selection: Use 10-12% SDS-PAGE gels as MOCS3 has a molecular weight of approximately 49-50 kDa.

• Transfer conditions: Transfer to PVDF membrane at 100V for 1.5 hours in cold transfer buffer containing 20% methanol.

• Blocking: Block with 5% non-fat milk in TBST for 1 hour at room temperature.

• Primary antibody incubation: Dilute MOCS3 antibody according to manufacturer recommendations (typically 1:1000 to 1:2000) and incubate overnight at 4°C .

• Secondary antibody: Use HRP-conjugated anti-rabbit IgG (1:5000) for 1 hour at room temperature.

• Detection: Develop using enhanced chemiluminescence substrate.

When troubleshooting, it's important to note that the N-terminus of recombinant His₆-tagged MOCS3-RLD can be partially gluconoylated (mass increment of 178 Da), which may result in protein heterogeneity but does not affect activity . This may present as multiple closely spaced bands on a Western blot.

What controls should be used when working with MOCS3 antibodies?

Proper experimental controls are essential for validating MOCS3 antibody results:

Positive controls:

• Human cell lines with known MOCS3 expression (e.g., HEK293, HeLa)

• Recombinant MOCS3 protein

• Tissue samples with documented MOCS3 expression (preferably from publications using the same antibody)

Negative controls:

• MOCS3 knockdown or knockout cells (using siRNA or CRISPR-Cas9)

• Irrelevant primary antibody of the same isotype

• Secondary antibody only controls to assess non-specific binding

Peptide competition assay: Pre-incubate the MOCS3 antibody with the immunizing peptide (if available) to confirm specificity. For commercially available antibodies, the immunogen typically corresponds to recombinant fragment protein within Human MOCS3 aa 200-250 to C-terminus .

Including these controls in your experimental design will significantly enhance the reliability and interpretability of your findings, particularly when presenting them for publication.

How does the structure of MOCS3 influence antibody epitope selection?

MOCS3 contains two functionally distinct domains that impact antibody epitope selection and experimental design. The N-terminal domain resembles the Escherichia coli MoeB protein and is responsible for adenylation activity. The C-terminal segment displays similarities to the sulfurtransferase rhodanese and is termed the MOCS3 rhodanese-like domain (MOCS3-RLD) . This domain architecture has significant implications for antibody development and application.

The MOCS3-RLD contains four cysteine residues, with only C412 (located in the six-amino acid active loop) being conserved across homologous proteins in other organisms. ESI-MS/MS studies have provided direct evidence that a persulfide group is exclusively formed on this C412 residue, which is critical for sulfurtransferase activity . Additionally, a disulfide bridge between C316 and C324 has been identified, which may affect protein folding and stability.

When selecting antibodies for specific research applications, consider which domain is most relevant to your research question:

Most commercial antibodies target regions within the C-terminal portion (aa 200-460) , making them suitable for studying the sulfurtransferase functions of MOCS3 but potentially limiting their utility for investigating N-terminal domain-specific functions.

What approaches can resolve discrepancies in MOCS3 expression data?

Researchers often encounter discrepancies between antibody-based detection methods and gene expression analyses. To resolve these discrepancies when studying MOCS3, a multi-faceted approach is recommended:

• Compare multiple antibodies: Use at least two different MOCS3 antibodies that target different epitopes to confirm expression patterns. Commercial antibodies like ab154107 and ab229827 target different regions within the C-terminal domain .

• Correlate with transcriptomic data: Compare protein expression with mRNA levels using RT-qPCR or RNA-seq data. Public databases like TCGA can provide valuable gene expression information for various tissue types and disease states, as demonstrated in PAICS studies .

• Implement orthogonal techniques:

  • Mass spectrometry to confirm protein identity and potential post-translational modifications

  • Proximity ligation assay (PLA) to verify protein-protein interactions in situ

  • CRISPR knockout/knockdown validation followed by rescue experiments

• Consider post-translational modifications: The persulfide formation on C412 and the disulfide bridge between C316 and C324 in MOCS3-RLD may affect antibody binding. Perform experiments under both reducing and non-reducing conditions.

• Evaluate subcellular localization: Discrepancies may arise from differences in protein localization rather than expression levels. Combine fractionation studies with immunofluorescence to determine if MOCS3 localization varies across experimental conditions.

By systematically addressing potential sources of discrepancy, researchers can generate more reliable and comprehensive data on MOCS3 expression and function.

How can MOCS3 antibodies be used to investigate sulfurtransferase activity?

MOCS3's sulfurtransferase activity, mediated through its rhodanese-like domain, is critical for both tRNA modification and molybdenum cofactor biosynthesis. To investigate this activity using MOCS3 antibodies, consider the following methodological approaches:

• Activity-state specific detection: Develop an experimental strategy that differentiates between active (persulfide-bound) and inactive MOCS3:

  • Use alkylating agents like iodoacetamide or N-ethylmaleimide to trap the persulfide group

  • Perform Western blotting under non-reducing conditions to preserve the persulfide at C412

  • Compare detection with reducing agents like DTT, which would cleave the persulfide

• Co-immunoprecipitation (Co-IP) studies:

  • Use MOCS3 antibodies to pull down protein complexes

  • Analyze interaction with known partners like URM1 and MOCS2A

  • Identify novel binding partners using mass spectrometry

• In vitro sulfurtransferase assay: Combine immunopurified MOCS3 with:

  • Fluorescent or radiolabeled sulfur donors

  • Potential acceptor proteins

  • Measure transfer efficiency under various conditions

• Immunocytochemistry: Investigate co-localization of MOCS3 with:

  • Sulfur donor proteins (e.g., NFS1)

  • Sulfur acceptor proteins (URM1, MOCS2A)

  • Sites of tRNA modification

According to biochemical studies, MOCS3-RLD can catalyze the transfer of sulfur from thiosulfate to cyanide and can provide the sulfur for thiocarboxylation of MOCS2A in defined in vitro systems . By targeting the C-terminal domain with specific antibodies, researchers can further characterize this crucial enzymatic activity.

What experimental approaches can determine the role of MOCS3 in disease pathways?

While MOCS3's fundamental biochemical functions are increasingly understood, its role in disease pathways remains an area of active investigation. To elucidate potential disease associations, consider these methodological approaches using MOCS3 antibodies:

• Expression profiling in disease models:

  • Compare MOCS3 levels between normal and disease tissues using IHC-P

  • Assess correlation with disease progression or severity

  • Analyze subcellular localization changes using IF microscopy

• Functional impact analysis:

  • CRISPR-Cas9 knockout or knockdown studies followed by phenotypic analysis

  • Rescue experiments with wild-type vs. mutant MOCS3

  • Monitor downstream pathways dependent on molybdenum cofactor

• Post-translational modification assessment:

  • Investigate alterations in persulfide formation at C412

  • Examine potential phosphorylation, ubiquitination, or other modifications

  • Compare PTM patterns between normal and disease states

• Interactome analysis in disease context:

  • Perform proximity-dependent biotin identification (BioID) with MOCS3 as bait

  • Compare interactome in normal vs. disease states

  • Validate key interactions with co-IP using MOCS3 antibodies

• Pathway integration:

  • Investigate connections to known disease pathways, similar to PI3K-AKT signaling studies with PAICS

  • Monitor effects of MOCS3 modulation on DNA damage response, as observed with PAICS

  • Assess impact on cell cycle regulation

By systematically applying these approaches, researchers can potentially identify novel roles for MOCS3 in disease processes, opening new avenues for diagnostic and therapeutic development.

How can artificial intelligence approaches complement MOCS3 antibody research?

Recent advances in artificial intelligence (AI) are transforming molecular biology research. For MOCS3 studies, AI approaches can complement traditional antibody-based methods:

• Protein structure prediction:

  • AI models like AlphaFold can predict MOCS3 structures, particularly the rhodanese-like domain

  • These predictions can inform epitope selection for antibody development

  • Structural insights can help interpret experimental findings

• Binding affinity prediction:

  • Tools similar to A2binder can predict interactions between MOCS3 and its binding partners

  • These predictions can guide co-IP experiments with MOCS3 antibodies

  • As with the SARS-CoV-2 antibody research, pre-trained language models can assist in analyzing protein-protein interactions

• Sequence-structure-function relationships:

  • AI can identify critical residues beyond the known C412 persulfide site

  • These insights can guide site-directed mutagenesis studies

  • Results can be validated using MOCS3 antibodies

• Image analysis in microscopy:

  • AI-enhanced image processing for IF and IHC data with MOCS3 antibodies

  • Quantitative analysis of co-localization with binding partners

  • Automated detection of subcellular distribution patterns

• Multi-omics data integration:

  • Integrating antibody-based MOCS3 protein data with transcriptomics, metabolomics

  • Identifying novel associations and regulatory networks

  • Predicting functional consequences of MOCS3 modulation

Similar to the approach used in developing PALM-H3 for antibody generation , researcher-specific AI models could be trained on MOCS3-related data to facilitate hypothesis generation and experimental design, ultimately accelerating discovery in this field.

How to select the optimal MOCS3 antibody for specific research applications?

Selecting the appropriate MOCS3 antibody requires careful consideration of several factors based on your specific research goals:

• Application compatibility: Different antibodies perform optimally in different applications. Based on available commercial options:

  • For Western blotting: All listed MOCS3 antibodies (ab154107, ab229827, ABIN7307034) are validated

  • For IHC-P: ab229827 and ABIN7307034 are suitable choices

  • For Immunofluorescence: ABIN7307034 has been validated

• Epitope location: Consider which domain of MOCS3 is relevant to your research:

  • For studying the C-terminal sulfurtransferase activity: Antibodies targeting aa 200-460 (all referenced antibodies)

  • For investigating specific structural features: Select antibodies whose epitopes include or exclude regions of interest

• Validation evidence: Review the validation data available from manufacturers:

  • Publication citations demonstrate real-world utility

  • Species reactivity should match your experimental system

  • Positive controls should be relevant to your research

• Antibody format: Consider the most appropriate format:

  • Unconjugated for maximum flexibility across applications

  • Directly conjugated for specific applications like flow cytometry or multiplexed imaging

• Clonality considerations: All referenced MOCS3 antibodies are polyclonal rabbit antibodies , which offer:

  • Higher sensitivity due to recognition of multiple epitopes

  • Potentially greater batch-to-batch variation

  • Good performance across applications

When planning critical experiments, validating antibody performance in your specific experimental system is strongly recommended, regardless of manufacturer claims.

What are common pitfalls and troubleshooting strategies when using MOCS3 antibodies?

Researchers using MOCS3 antibodies may encounter several common challenges. Here are methodological solutions for each:

• Non-specific banding in Western blots:

  • Increase blocking stringency (5-10% milk or BSA)

  • Optimize primary antibody dilution (try 1:1000 to 1:5000 range)

  • Include 0.1% Tween-20 in all washing and antibody incubation steps

  • Consider using PVDF rather than nitrocellulose membranes

  • Be aware that the N-terminus of recombinant MOCS3 can be partially gluconoylated, causing heterogeneity

• Weak or absent signal:

  • Ensure sample contains adequate MOCS3 expression

  • Reduce washing stringency

  • Increase antibody concentration

  • Extend primary antibody incubation time (overnight at 4°C)

  • Use enhanced sensitivity detection systems (e.g., enhanced chemiluminescence)

• Inconsistent staining in IHC/IF:

  • Optimize antigen retrieval (try citrate buffer pH 6.0 vs. EDTA buffer pH 9.0)

  • Ensure proper fixation (4% paraformaldehyde or 10% neutral buffered formalin)

  • Block endogenous peroxidase activity for IHC

  • Include image acquisition controls to ensure consistent exposure settings

• Failed co-IP experiments:

  • Consider native protein conformation - some epitopes may be inaccessible

  • Test different lysis buffers (RIPA vs. NP-40 vs. digitonin-based)

  • Cross-link antibody to beads to prevent antibody co-elution

  • Optimize salt concentration to maintain protein-protein interactions

• Batch-to-batch variability:

  • Purchase sufficient antibody for complete experimental series

  • Always include positive controls with established performance

  • Consider lot-testing when ordering replacement antibody

  • Document lot numbers in experimental records

When troubleshooting persistent issues, remember that the MOCS3 rhodanese-like domain contains a critical persulfide group on C412 and a disulfide bridge between C316 and C324 , which may affect antibody recognition under different experimental conditions.

How might MOCS3 antibodies contribute to understanding post-translational modifications?

MOCS3 undergoes and facilitates several interesting post-translational modifications (PTMs) that could be further investigated using antibody-based approaches:

• Persulfide formation investigation:

  • Develop modification-specific antibodies that selectively recognize the persulfide-modified C412 residue

  • Use existing antibodies in combination with mass spectrometry to track persulfide formation kinetics

  • Investigate environmental and cellular conditions that regulate persulfide formation

• Thiocarboxylation pathway mapping:

  • Track the transfer of sulfur from MOCS3 to target proteins URM1 and MOCS2A

  • Develop antibodies that specifically recognize thiocarboxylated proteins

  • Investigate the regulatory mechanisms controlling this modification

• N-terminal gluconoylation characterization:

  • Study the functional significance of the identified N-terminal gluconoylation (mass increment of 178 Da)

  • Develop antibodies specific to the gluconoylated form

  • Investigate whether this modification occurs in vivo or is an artifact of recombinant expression

• Disulfide bond dynamics:

  • Investigate the formation and reduction of the C316-C324 disulfide bridge

  • Examine how redox conditions affect MOCS3 structure and function

  • Develop conformation-specific antibodies that distinguish between oxidized and reduced forms

• Integration with other PTM pathways:

  • Examine potential crosstalk between MOCS3-mediated modifications and other PTMs

  • Investigate how MOCS3 activity might be regulated by phosphorylation, ubiquitination, or other modifications

  • Develop multiplexed detection methods for simultaneous tracking of multiple modifications

These approaches could significantly advance our understanding of how MOCS3 function is regulated and how it interfaces with other cellular pathways.

What emerging technologies could enhance MOCS3 antibody-based research?

Several cutting-edge technologies are poised to revolutionize antibody-based research on MOCS3:

• Single-cell proteomics:

  • Analyze MOCS3 expression and localization at the single-cell level

  • Correlate with functional outcomes in heterogeneous cell populations

  • Identify rare cell populations with unique MOCS3 expression patterns

• Spatial proteomics:

  • Map MOCS3 distribution within cells and tissues with nanometer precision

  • Correlate MOCS3 localization with functional domains in cells

  • Use multiplexed imaging to simultaneously detect MOCS3 and its binding partners

• Proximity labeling approaches:

  • Fuse MOCS3 with proximity labeling enzymes (BioID, APEX)

  • Identify proteins in close proximity to MOCS3 in living cells

  • Validate interactions using traditional antibody-based methods

• Genetically encoded sensors:

  • Develop FRET-based sensors for monitoring MOCS3 activity in real-time

  • Create biosensors for detecting thiocarboxylation events

  • Monitor sulfur transfer reactions in living cells

• Antibody engineering approaches:

  • Leverage AI-based approaches similar to those used for SARS-CoV-2 antibodies

  • Develop single-domain antibodies or nanobodies against MOCS3

  • Create activity-modulating antibodies that can enhance or inhibit MOCS3 function

These technological advances, when applied to MOCS3 research, could provide unprecedented insights into its cellular functions and potential roles in health and disease, similar to how advanced methodologies have revealed new aspects of proteins like PAICS in cancer research .